Answers are grounded in this paper and cite their sources.
We propose the term deficiency of the interleukin-1-receptor antagonist, or DIRA, to denote this autosomal recessive autoinflammatory disease caused by mutations affecting IL1RN. The absence of interleukin-1-receptor antagonist allows unopposed action of interleukin-1, resulting in life-threatening systemic inflammation with skin and bone involvement. (ClinicalTrials.gov number, NCT00059748.)
No takes yet. Share an insight, caveat, or question.
Aksentijevich et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: